» Articles » PMID: 34082764

Juvenile Idiopathic Arthritis in Harlequin Ichthyosis, a Rare Combination or the Clinical Spectrum of the Disease? Report of a Child Treated with Etanercept and Review of the Literature

Overview
Publisher Biomed Central
Specialty Pediatrics
Date 2021 Jun 4
PMID 34082764
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Harlequin ichthyosis (HI) is the most severe phenotype of autosomal recessive congenital ichthyosis. Juvenile Idiopathic Arthritis (JIA) represents a heterogenous group of disorders all sharing the clinical manifestation of chronic arthritis. Association of HI and chronic arthritis has been reported in few cases.

Case Presentation: We report the case of a child with HI who developed a severe form of chronic polyarthritis during the first years of life, treated with repeated multiple joint injections, methotrexate and etanercept with good response and without any adverse events.

Conclusion: The reported case and the literature review highlighted the presence of a peculiar severe seronegative polyarthritis with early onset in a series of patients with HI, suggesting that polyarthritis may be a specific manifestation of HI, rather than a rare combination of two separate conditions.

Citing Articles

Short histological kaleidoscope - recent findings in histology. Part III.

Constantin A, Mihu C, Bosca A, Melincovici C, Marginean M, Jianu E Rom J Morphol Embryol. 2023; 64(2):115-133.

PMID: 37518868 PMC: 10520383. DOI: 10.47162/RJME.64.2.01.


Developments in pediatrics in 2020: choices in allergy, autoinflammatory disorders, critical care, endocrinology, genetics, infectious diseases, microbiota, neonatology, neurology, nutrition, ortopedics, respiratory tract illnesses and rheumatology.

Caffarelli C, Santamaria F, Procaccianti M, Piro E, Delle Cave V, Borrelli M Ital J Pediatr. 2021; 47(1):232.

PMID: 34876198 PMC: 8650733. DOI: 10.1186/s13052-021-01184-4.


Correction to: Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature.

Baldo F, Brena M, Carbogno S, Minoia F, Lanni S, Guez S Pediatr Rheumatol Online J. 2021; 19(1):115.

PMID: 34301279 PMC: 8306257. DOI: 10.1186/s12969-021-00603-4.

References
1.
Kelsell D, Norgett E, Unsworth H, Teh M, Cullup T, Mein C . Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet. 2005; 76(5):794-803. PMC: 1199369. DOI: 10.1086/429844. View

2.
Vahlquist A, Fischer J, Torma H . Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017; 19(1):51-66. PMC: 5797567. DOI: 10.1007/s40257-017-0313-x. View

3.
Rodriguez-Pazos L, Ginarte M, Vega A, Toribio J . Autosomal recessive congenital ichthyosis. Actas Dermosifiliogr. 2013; 104(4):270-84. DOI: 10.1016/j.adengl.2011.11.021. View

4.
Rajpopat S, Moss C, Mellerio J, Vahlquist A, Ganemo A, Hellstrom-Pigg M . Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases. Arch Dermatol. 2011; 147(6):681-6. DOI: 10.1001/archdermatol.2011.9. View

5.
Harvey H, Shaw M, Morrell D . Perinatal management of harlequin ichthyosis: a case report and literature review. J Perinatol. 2009; 30(1):66-72. DOI: 10.1038/jp.2009.100. View